<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295945</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459963</org_study_id>
    <secondary_id>UCSF-03423</secondary_id>
    <secondary_id>UCSF-H10588-24197-02</secondary_id>
    <nct_id>NCT00295945</nct_id>
  </id_info>
  <brief_title>Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer</brief_title>
  <official_title>Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the&#xD;
      covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer&#xD;
      surgery. It is not yet known whether epidural analgesia is more effective than&#xD;
      patient-controlled analgesia in controlling pain in patients who have undergone surgery for&#xD;
      gynecologic cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying epidural analgesia to see how well it&#xD;
      works compared to patient-controlled analgesia in treating patients who have undergone&#xD;
      surgery for gynecologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether the gradual weaning of an epidural opioid can shorten the duration of&#xD;
           postoperative ileus, without worsening pain control, in patients who have undergone&#xD;
           surgery for gynecologic cancer.&#xD;
&#xD;
        -  Compare postoperative pain management in patients treated with perioperative epidural&#xD;
           analgesia vs patient controlled analgesia.&#xD;
&#xD;
        -  Compare time to ambulation, return of bowel function, and readiness for hospital&#xD;
           discharge in patients treated with these pain management interventions.&#xD;
&#xD;
        -  Compare the incidence of perioperative complications (e.g., bleeding, hypotension,&#xD;
           thromboembolic events, pneumonia, wound infection, myocardial infection, or death) in&#xD;
           patients treated with these pain management interventions.&#xD;
&#xD;
      OUTLINE: This is a partially randomized, double-blind, parallel-group study. Patients choose&#xD;
      between epidural analgesia or patient controlled analgesia (PCA) for perioperative pain&#xD;
      management. Patients for whom an epidural is contraindicated receive a PCA. Patients are&#xD;
      assigned to 1 of 2 treatment groups. Patients in group 1 are stratified according to bowel&#xD;
      resection surgery (yes vs no) and prior abdominal surgery (yes vs no).&#xD;
&#xD;
        -  Group 1 (epidural): Patients undergo placement of a thoracic epidural catheter followed&#xD;
           by abdominal/pelvic surgery. Patients then begin an epidural infusion of ropivacaine&#xD;
           hydrochloride and fentanyl immediately after surgery (postoperative day 0). Patients may&#xD;
           also be supplemented with a patient controlled demand dose. The day after surgery&#xD;
           (postoperative day 1), patients are randomized (as long as there is adequate pain&#xD;
           control) to 1 of 2 epidural management arms.&#xD;
&#xD;
             -  Arm I: Patients continue to receive the epidural infusion until they can be weaned&#xD;
                to oral pain medication.&#xD;
&#xD;
             -  Arm II: Patients undergo daily weaning of the fentanyl concentration of the&#xD;
                epidural infusion.&#xD;
&#xD;
        -  Group 2 (PCA): Patients begin PCA immediately after undergoing abdominal/pelvic surgery&#xD;
           (postoperative day 0). Patients receive a demand schedule of hydromorphone IV until they&#xD;
           can be weaned to oral pain medication.&#xD;
&#xD;
      In both groups, the Gynecologic Oncology pain service may make adjustments to the epidural&#xD;
      infusion or PCA for optimal pain management until the patient can be weaned to oral pain&#xD;
      medication.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 224 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to return to bowel function at discharge</measure>
    <time_frame>Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score daily</measure>
    <time_frame>Days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pain</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>PCA</arm_group_label>
    <description>Patient-controlled intravenous analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCEA</arm_group_label>
    <description>Perioperative patient-controlled epidural analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl citrate</intervention_name>
    <arm_group_label>PCEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydromorphone hydrochloride</intervention_name>
    <arm_group_label>PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine hydrochloride</intervention_name>
    <arm_group_label>PCEA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of a gynecologic malignancy&#xD;
&#xD;
          -  Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the&#xD;
             gynecologic oncology service at the University of California San Francisco Medical&#xD;
             Center&#xD;
&#xD;
          -  No failed epidural catheters (for patients choosing epidural analgesia)&#xD;
&#xD;
          -  No lumbar epidurals (for patients choosing epidural analgesia)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of a gynecologic malignancy&#xD;
&#xD;
          -  Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the&#xD;
             gynecologic oncology service at the University of California San Francisco Medical&#xD;
             Center&#xD;
&#xD;
          -  No failed epidural catheters (for patients choosing epidural analgesia)&#xD;
&#xD;
          -  No lumbar epidurals (for patients choosing epidural analgesia)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee-may Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>perioperative/postoperative complications</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage I endometrial carcinoma</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>stage IA fallopian tube cancer</keyword>
  <keyword>stage IB fallopian tube cancer</keyword>
  <keyword>stage IC fallopian tube cancer</keyword>
  <keyword>stage IIA fallopian tube cancer</keyword>
  <keyword>stage IIB fallopian tube cancer</keyword>
  <keyword>stage IIC fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>stage IA ovarian epithelial cancer</keyword>
  <keyword>stage IB ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IA ovarian germ cell tumor</keyword>
  <keyword>stage IB ovarian germ cell tumor</keyword>
  <keyword>stage IC ovarian germ cell tumor</keyword>
  <keyword>stage IIA ovarian germ cell tumor</keyword>
  <keyword>stage IIB ovarian germ cell tumor</keyword>
  <keyword>stage IIC ovarian germ cell tumor</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

